What is Biomodels?
BioModels operates as a specialized Contract Research Organization (CRO) dedicated to advancing preclinical research for a global clientele spanning pharmaceutical, biotech, start-up, and academic institutions. The company excels in a diverse array of disease models, including those related to inflammatory and immune-mediated conditions, cancer supportive care, and fibrosis. Their service portfolio encompasses sophisticated in vitro and ex vivo studies, alongside advanced microbiome research and various surgical models, all designed to provide bespoke solutions tailored to the unique requirements of each client's research objectives. Biomodels is committed to delivering high-impact, actionable data through a deeply collaborative process, guiding clients from initial study design through to the final comprehensive reporting.
How much funding has Biomodels raised?
Biomodels has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Biomodels?
With its recent large-scale late-stage funding, Biomodels is strategically positioned to enhance its research capabilities and expand its service offerings. The substantial capital infusion is expected to fuel advancements in their specialized disease models, potentially leading to the development of new research methodologies and technologies. This investment will likely enable Biomodels to deepen its collaborations with existing partners and attract new clients seeking cutting-edge preclinical research support. The company's focus on complex disease areas and its commitment to data integrity suggest a continued emphasis on innovation and scientific rigor as it navigates its next phase of growth.
See full Biomodels company page
